Epilepsy, treatment

Barbiturates are among the drugs classified as central nervous system (CNS) depressants. These drugs depress or slow down the activity of nerves that control emotions and bodily functions such as breathing. Barbiturates are prescribed as a sedative that calms the patient or as a hypnotic that helps a person sleep. Other uses include epilepsy treatment and anesthesia before surgery. 

At the close of the twentieth century, the DEA reported that barbiturates represented about 20% of all depressant prescriptions in the United States. Uses ranged from epilepsy treatment to assisted suicide in Oregon. In 1997, Oregon voters approved the Death with Dignity Act, which allows doctors to prescribe lethal dosages of barbiturates to terminally ill people. 

Shorvan, S. D. Handbook of Epilepsy Treatment. Oxford Blackwell Science, 2000. Vermeulen, J. and Aldenkamp, A. P. Cognitive side effects of chronic antiepileptic drug treatment a review of 25 years research. Epilepsy Res. 22 (1995) 65-80. 

By 1912, von Mering and Fischer developed and commercially introduced a new barbiturate compound for sleep and anxiety called phenobarbital or Luminal. However, this medication quickly found its place as treatment for a very different medical condition, epilepsy, which is a condition of periodic, unprovoked convulsions or seizures. The main goal of epilepsy treatment is to decrease the frequency of seizures. Alfred Hauptmann discovered the anti-epileptic properties of phenobarbital accidentally. A 1912 report by Hauptmann described epileptic patients who were given phenobarbital for sedation and incidentally had fewer seizures. Seizures are caused by an abnormal impulse in the brain, which spreads and sends inappropriate message to the body. These messages result in... 

Hung CC, Tai JJ, Lin CJ, et al. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005 6(4) 411-417. 

HPLC is an indispensable tool in the laboratory Therapeutic drug monitoring Monitoring of asthma treatment Management of epilepsy treatment A qualitative analysis tool J Testing incoming raw materials... 

When lamotrigine is added to epilepsy treatment that includes valproate (ages 12 and older) for the first 2 weeks administer 25 mg every other day at week 3 increase to 25 mg/day every 1-2 weeks can increase by 25-50 mg/day usual maintenance dose 100-400 mg/day in 1-2 doses or 100-200 mg/day if lamotrigine is added to valproate alone... 

Low bone density leads to an increased risk of fractures. There was a 30% increased risk of non-seizure-related fractures in 348 non-institutionalized patients with epilepsy compared with a large control population (129). For non-seizure-related fractures the crude fracture rate was 1.6 fractures per 100 patient-years of observation a similar rate (1.4) has been found in men with epilepsy (122). In addition, in children with epilepsy, treatment with valproic acid and/or lamotrigine for more than... 

Datta PK, Crawford PM. Refractory epilepsy treatment with new antiepileptic drugs. Seizure 2000 9(l) 51-7. 

A study to document the outcomes of epilepsy treatment, conducted by Hirsch and Van Den Eeden (1997), illustrates some of the challenges associated with collecting burden of illness data. The traditional clinical measure of seizure frequency is no longer considered appropriate as the sole measure of outcome of treatment or surgical intervention. The additional variables to document the burden of illness that were found illustrate the gap between the type of data desired and what is available. Hitherto, QOL had been assessed in epilepsy patients using no fewer than 12 different... 

This mutant line will be a useful model for testing the effectiveness of pharmacological intervention in preventing cell loss, an important goal of epilepsy treatment in human patients. Since other Na" " channels are also expressed in hippocampal neurons, it seems likely that delayed inactivation of SCN1A, SCN3A or SCN8A could also result in seizures. 

In conclusion, PUFAs play multiple important roles in brain development and the regulation of neuronal excitability. Exploration of their possible function in epilepsy treatment is just now beginning. The possibility that a PUFA diet , analogous to the existing ketogenic diet (Table 3), could play a role in the battle against epilepsy is indeed tantalizing. 

It is clear that the cheapest drugs in epilepsy (e.g., phenobarbital) are not the best because of the number of side effects. Eurther drug therapy that would control seizures, decrease side effects, improve the quality of life, and reduce the use of other health care resources would be cost-effective. Because epilepsy treatment continues to be... 

Perspectives of epilepsy treatment by a herbal mixture prescription saikokeishito-ka-shakuyaku (SK) 01YZ295. 

Bromide, the almost forgotten first antiepileptic, is again successfully used for epilepsy treatment, especially with patients for whom other antiepileptics do not show any effect [539]. Therefore, frequent control of the bromide level in the patient s serum and urine is required. Because it has been observed that an above-average intake of sodium chloride leads to a rapid decrease of the bromide level in adolescent patients, Juergens [540] investigated the possibility of a correlation between bromide and chloride concentrations in serum and urine. 

Bromide, the almost forgotten first antiepileptic, is again successfully used for epilepsy treatment, especially with patients for whom other antiepileptics do not show any effect [313]. Therefore, frequent control of the bromide level in the... 

Perucca P, Gilliam FG, Schmitz B. Epilepsy treatment as a predeterminant of psychosocial ill health. Epilepsy Behav 2009 15(Suppl 1) S46-50. 

Epilepsy Treatment-emergent adverse events of clobazam were studied in an open-label trial in 267 patients with Lennox-Gastaut syndrome who received clobazam at dosages <80 mg per day [6 ]. In total, 82% of patients experienced treatment-emergent adverse event. The most common adverse events were upper respiratory tract infection (18.4%), fall (14.2%), pneumonia (13.9%), somnolence (12.7%), otitis media (12.0%), pyrexia (10.5%) and constipation (10.1%). The upper respiratory tract infection and pneumonia events occurred predominantly in paediatric patients. 

---